Skip to main content

Advertisement

Log in

Has drug therapy changed the natural history of Parkinson’s disease?

  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

This narrative review examines the effects of drug therapy on the natural history of Parkinson’s disease. In terms of modifying the underlying disease process, it is possible that immediate therapy, rather than deferred treatment, can have a positive effect on the underlying disease process. However, it is unlikely that drug therapy has changed mortality from the condition and there is no evidence that it can delay the onset of non-motor features such as dementia and falls. The beneficial effects of drug therapy on the motor symptoms of Parkinson’s disease are unquestionable, but these are at the expense of short-term dopaminergic side effects, long-term motor complications, and impulse control disorders. Major questions remain regarding which initial therapeutic approach should be taken which may possibly be answered by the ongoing PD MED trial. The beneficial effects of drug therapy on the motor features of Parkinson’s disease have had a fundamental impact on the suffering of patients. The mainstay of these therapies continues to be levodopa, although it is now used at lower doses than in the past and in combination with other drug classes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Clarke CE (1993) Mortality from Parkinson’s disease in England and Wales 1921–1989. J Neurol Neurosurg Psychiatry 56:690–693

    Article  CAS  PubMed  Google Scholar 

  2. Clarke CE (1995) Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord 10(3):250–256

    Article  CAS  PubMed  Google Scholar 

  3. Clarke C (2000) Mortality from Parkinson’s disease. J Neurol Neurosurg Psychiatry 68(2):254–255

    Article  CAS  PubMed  Google Scholar 

  4. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442

    CAS  PubMed  Google Scholar 

  5. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60(3):387–392

    Article  PubMed  Google Scholar 

  6. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al (2004) Levodopa and the progression of Parkinson’s disease [see comment]. N Engl J Med 351(24):2498–2508

    Article  CAS  PubMed  Google Scholar 

  7. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P et al (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol 51(5):604–612

    Article  CAS  PubMed  Google Scholar 

  8. Parkinson Study Group (2004) A controlled, randomised, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561–566

    Article  Google Scholar 

  9. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361(13):1268–1278

    Article  CAS  PubMed  Google Scholar 

  10. Clarke CE (2008) Are delayed-start design trials to show neuroprotection in Parkinson’s disease fundamentally flawed? Mov Disord 23(6):784–789

    Article  PubMed  Google Scholar 

  11. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ et al (2008) Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev (2):CD006564

  12. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE et al (2004) Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329(7466):593

    Article  CAS  PubMed  Google Scholar 

  13. Weintraub D (2008) Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol 64(Suppl 2):S93–S100

    PubMed  Google Scholar 

  14. Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y et al (2010) Rationale for delayed-start study of pramipexole in Parkinson’s disease: the PROUD study. Mov Disord 25:1627–1632

    Google Scholar 

Download references

Acknowledgments

The author would like to thank Drs. L. Pallan, M. Connock, and Prof. C. Hyde for their help in preparing Figs. 1 and 2 and Natalie Ives and Smitaa Patel in the University of Birmingham Clinical Trials Unit for the PD MED data.

Conflict of interest

Professor Clarke has received honoraria for lectures, travel expenses for conferences, and unrestricted educational grants from Boehringer Ingelheim, GlaxoSmithKline, Lundbeck, Orion Pharma, Novartis, Teva, UCB, and Valeant.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. E. Clarke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clarke, C.E. Has drug therapy changed the natural history of Parkinson’s disease?. J Neurol 257 (Suppl 2), 262–267 (2010). https://doi.org/10.1007/s00415-010-5716-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-010-5716-z

Keywords

Navigation